Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | DHFR | P00374 | 3/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063201 | 0.84 | PIK3CA (0.47) | PIK3CAMTORDHFRCCNT1CCNA2 | |
| SCHEMBL3337583 | 0.82 | MAP4K4 (0.47) | PIK3CAMTORDHFR | |
| SCHEMBL4408579 | 0.77 | NOS1 (0.50) | PIK3CAMPO | |
| SCHEMBL4064081 | 0.76 | CHRNA7 (0.41) | PIK3CAMTORCCNT1CCNA2CDK2 | |
| SCHEMBL655418 | 0.73 | PIK3CA (0.45) | PIK3CAMTORDHFR | |
| SCHEMBL3785844 | 0.72 | MPO (0.43) | DHFRMPO | |
| SCHEMBL3335372 | 0.72 | ADORA2A (0.45) | PIK3CAMTORDHFRCCNA2CDK2 | |
| SCHEMBL3336378 | 0.71 | SCN9A (0.47) | PIK3CAMTORCCNA2CDK2 | |
| SCHEMBL3764208 | 0.71 | PIK3CG (0.49) | PIK3CAMPO | |
| SCHEMBL3755253 | 0.71 | GRIN2B (0.39) | PIK3CADHFRMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851217-B1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2009-02-11 | — | — | EP | claimed |
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | 4 AZA BIOSCIENCE NV (BE) | 2008-12-18 | — | — | US | claimed |
| EP-1851217-A1 | SUBSTITUTED PYRIDO(2,3-D)PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2007-11-07 | — | — | EP | claimed |
| WO-2006087229-A1 | SUBSTITUTED PYRIDO (2 , 3-D) PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2006-08-24 | — | — | WO | claimed |
| EP-1851217-B1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2009-02-11 | — | — | EP | disclosed |
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | 4 AZA BIOSCIENCE NV (BE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | PNPO, TPMT, TNF | PIK3CA 1151/4885MTOR 1681/4885DHFR 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.